In a phase 1/2 trial reported at the American Association of Cancer Research (AACR) congress, there were preliminary signs that the approach could work. BioNTech said its CAR-T (BNT211 ...

16 analysts have expressed a variety of opinions on BioNTech BNTX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

Summit's ivonescimab data has sparked interest in BioNTech's BNT327, and its potential to follow a similar path and gain value. Goldman incorporates risk-adjusted revenue forecasts that currently ...

Professors Ugur Sahin and Ozlem Tureci co-founded the German company BioNTech in 2008, exploring new technology involving messenger RNA (mRNA), to treat cancer. When the pandemic struck they ...

In the latest quarter, 15 analysts provided ratings for BioNTech (NASDAQ:BNTX), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing ...

Pfizer and BioNTech have started clinical trials of a new Covid vaccine which targets the Omicron variant. The companies plan to test the protection gained from the new vaccine as a booster jab ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...